Murdoch D, Lyseng-Williamson KA (2005). «Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis». BioDrugs. 19 (5): 323–5. PMID16207073. doi:10.2165/00063030-200519050-00005
nih.gov
ncbi.nlm.nih.gov
Murdoch D, Lyseng-Williamson KA (2005). «Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis». BioDrugs. 19 (5): 323–5. PMID16207073. doi:10.2165/00063030-200519050-00005
Kappos, L; Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. (2009). «Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.». Lancet Neurol.: 2009;8(11):987-97. PMID19748319A referência emprega parâmetros obsoletos |coautor= (ajuda)